



Haematological Neoplasms: Diagnosis and Management

Guest Editors:

Dr. Stefano Ascani

Associate Professor of Pathology,
Former Director of Pathology at
the University Hospital of Terni,
Perugia, Italy

Dr. Francesca Sanguedolce

Department of Pathology,
University of Foggia School of
Medicine, 71121 Foggia, Italy

Dr. Magda Zanelli

Pathology Unit, Azienda USL-
IRCCS di Reggio Emilia, 42123
Reggio Emilia, Italy

Deadline for manuscript
submissions:

closed (30 September 2023)

Message from the Guest Editors

Dear Colleagues,

The latest WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition, dates back to 2017, and there is a huge ongoing work for the new edition to be published within the coming years as part of the novel 5th Edition series. This work is focused on the analysis, discussion, and potential endorsement of the recent advances in the pathology and molecular biology of haematological neoplasms.

We are pleased to invite you to submit your research works to this Special Issue, which aims to shape the current landscape of the diagnosis and management of haematological neoplasms of both myeloid and lymphoid origin by critically assessing the more recent technological advances in the recognition of novel pathological entities, the detection of prognostic and predictive biomarkers, and the application of precision medicine tools.

Research areas may include (but are not limited to) ancillary techniques, the identification of prognostic/predictive biomarkers, issues in the diagnosis/differential diagnosis of challenging entities, and the current role of pathology in tailored therapy and precision medicine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **MEDLINE**, **PMC**, **Embase**, and **other databases**.

Journal Rank: JCR - Q2 (Oncology)

Contact Us

Current Oncology Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/currenconcol
currentoncology@mdpi.com
[X@CurrentOncology](https://twitter.com/CurrentOncology)